Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562870 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
A Phase 2 study of Myelofibrosis, sponsored by Karyopharm Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
- 20
- Study locations
NCT04562870 is a Phase 2 study of Myelofibrosis that is active but no longer recruiting, run by Karyopharm Therapeutics. The registered enrollment target is 112 participants, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT04562870, a Phase 2 study of Myelofibrosis, is active but no longer recruiting, sponsored by Karyopharm Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians' choice of treatment.
Conditions Studied
Interventions
- DRUG Selinexor
- OTHER Physician's Choice Treatment
Study Locations (20)
Other
- Centre Hospitalier Universitaire d'Angers (CHU Angers) - Angers
- Università degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - Dipartimento di medicina sperimentale e clinica - Florence
- Azienda Unita Sanitaria Locale Latina - Ospedale Santa Maria Goretti - Latina
- University of Perugia Department of Medicine Hematology Section - Perugia
- Asst Settelaghi, Ospedale Di Circolo E Fondazione Macchi - Varese
- Pratia Onkologia Katowice - Katowice
Jiangsu
- Affiliated Hospital of Nantong University - Nantong
- The Second Affiliated Hospital of Soochow University - Suzhou
- Suzhou University -The First Affiliated Hospital - Suzhou
California
- The Oncology Institute of Hope and Innovation - Pasadena
Colorado
- Rocky Mountain Cancer Centers, LLP - Aurora
Illinois
- Illinois Cancer Specialist - Niles
Texas
- Texas Oncology - Northeast Texas - Tyler
Beijing Municipality
- Peking Union Medical College Hospital - Beijing
Hubei
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04562870
The ClinicalTrials.gov registry entry for NCT04562870 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 194-participant average among 61 other Myelofibrosis trials with a reported enrollment target (42% lower). The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Selinexor is the first listed.
NCT04562870 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Jiangsu, California.
Frequently Asked Questions
What is clinical trial NCT04562870 about?
NCT04562870 is a clinical study titled "A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis". This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician's choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be ra...
What is the current status of trial NCT04562870?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2021-03-17. Estimated completion is 2026-09.
What conditions does trial NCT04562870 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04562870?
The interventions under investigation include: Selinexor (DRUG), Physician's Choice Treatment (OTHER).
Who is sponsoring clinical trial NCT04562870?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04562870 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Texas, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.